Note: Page references in *italics* refer to Figures and Tables. Abbreviations used within the index are:
ARMS = at risk mental state; BLIPS = brief limited intermittent psychotic symptoms; ED:IT = Early Detection & Intervention Team (Birmingham); FETZ = Early Recognition and Intervention Centre for Mental Crises; UHR = Ultra High Risk.

abuse, childhood, 78, 79, 86, 118, 134, 135
adherence to treatment, 46–7
affective disorders, 76–7, 82
  *see also* depression
alcohol use, 93, 94, 95, 102
  *see also* substance use
antidepressants, 184
antipsychotic medication
  ED:IT, 83
  EDIE study, 112–13
future role, 5, 184
rationale for cognitive therapy and, 112
research methodologies, 2–3, 132
service development and, 104
stress–psychosis relation, 55–6
anxiety
  FETZ programme, 171, 177
  Hamilton Rating Scale, 32, 33
normalising, 141–2
UHR group treatment targets, 76, 77, 79, 82, 84, 85, 87
assertiveness, 175
assessment
  of at risk populations, 25–35
  CAARMS, 16–20, 32
case formulation and, 36–7
classificatory systems and, 77–8
co-morbidity, 77–8
dual diagnosis, 100–1, 104
mental health promotion, 87
as part of therapy, 26–7
role of, 25–6
substance users, 100–1, 104
treatment targets and, 87
types of, 28–35
of families, 159
at risk mental state (ARMS)
  assessing people in, 16–20, 25–35, 77–8, 87, 100–1, 104
BLIPS, 112–13, 130–2, 135–48
devvelopmental models, 80, 81, 135–6, 148
early social environment and, 133–5
ED:IT, 81–7
epidemiology, 1–2, 4
family support/interventions, 153–65, 170
future challenges, 181–5
group therapy, 83, 84, 85, 169–78, 183
identifying clients in, 7–21, 43–4
operational criteria for, 1, 130–2
relapse detection studies, 132–3
research issues, 1–5, 182
service development, 183–5
stress and
  *see* stress
substance use and, 76, 93–106
therapeutic alliance and, 41, 48–50
therapy for BLIPS, 112–13, 135–48
treating attenuated symptoms, 111–26
treatment targets, 75–88
use of term, 1, 130
attachment bonds, 133, 134, 135, 148
attention training, 183
attenuated psychotic symptoms, 9–10, 130–2
assessment interviews, 29, 30, 31
cognitive therapy, 111–24, 125–6
formulating, 117–18, 126
identifying at risk people, 12, 14–15, 43
impact on engagement, 44–5, 114
prevalence, 11
safety behaviours with, 115, 116, 124–5
auditory hallucinations
cognitive therapy for BLIPS, 136–7
meta-cognitive beliefs about, 122, 123–4
Morrison’s models of, 115–16, 117, 124
normalising, 118–19
safety behaviours, 124
trauma and, 79, 80, 118–19
basic symptoms, 13, 82, 129–30
Beck Cognitive Insight Scale (BCIS), 135
Beck Depression Inventory (BDI), 33
behaviour change
identifying at risk people, 9, 10
safety behaviours, 124–5
trans-theoretical model, 102
see also social isolation
Bonn Scale of Basic Symptoms (BSABS), 13, 82, 129, 130
brief limited intermittent psychotic symptoms (BLIPS), 112–13, 130–2, 135–48
acute phase, 139, 141
compassionate views of, 142, 147–8
engagement, 139–42
formulation, 137–9
images of BLIPS, 142, 143
meta-cognitions, 135, 146–7, 148
normalisation, 141–2
paranoia, 141–8
problem list, 137
recovery, 142–6
CAARMS (Comprehensive Assessment of At Risk Mental States), 16–20
Calgary Depression Scale (CDS), 32–3
cannabis use, 94, 95, 96–7, 98, 104–5
see also substance use
case formulation, 25, 35–8, 114–18, 125–6, 137–9
case management
ED:IT, 82, 83, 85
research methodologies, 2, 132
for stress management, 67
to enhance engagement, 114
childhood trauma, 134, 135
auditory hallucinations and, 79, 80, 118
UHR group treatment targets, 78, 79, 81, 86
classificatory systems, 77–8
client–clinician relationship, 26
therapeutic alliance, 41, 48–50, 158–9
see also engagement
clinician-rated symptom scales, 32–3
cognitive behaviour therapy (CBT)
assessment prior to, 25–6
for attenuated symptoms, 111–24, 125–6
common presenting problems, 113–14
core beliefs, 125–6
EDIE study, 112–13
engagement, 113–14
formulation, 114–18, 125–6
generating explanations, 119–20, 121–2
meta-cognitions, 120, 122–4
normalisation, 118–19
rationale, 112–13
for BLIPS, 112–13, 135–48
acute phase, 139, 141
compassionate views of BLIPS, 142, 147–8
engagement, 139–42
formulation, 137–9
images of BLIPS, 142, 143
meta-cognitions, 135, 146–7, 148
normalisation, 141–2
paranoia, 141–8
problem list, 137
recovery, 142–6
case formulation, 25, 35–8, 114–18, 125–6, 137–9
ED:IT, 81, 82, 83, 84, 85–6, 87
engagement see engagement
future challenges, 182–3
group interventions, 83, 84, 85, 170–8
research methodologies, 2, 3, 131–2
stress management, 67, 68
substance users, 99–106
therapeutic alliance, 41, 48–50
cognitive changes
BLIPS, 135
developmental processes, 80
engagement and, 44–5
identifying at risk people, 9, 10
cognitive models of psychosis, 115–16, 117, 124
combat, stress–psychosis relation, 58
communication exercises, 175
community education programmes, 47
cop-morbid disorders, 76–81, 82–3, 84, 85, 86, 87
see also substance use
compassion, 142, 147–8
Comprehensive Assessment of At Risk Mental States (CAARMS), 16–20
Coping Inventory for Stressful Situations (CISS), 66
coping with stress, 59–66, 68, 135, 155–6, 170
core beliefs, 125–6
danger, interpersonal, 142–3, 144–6, 148
dangerous behaviours, assessing, 30–1
Decision Grids, 103, 104
delusions
meta-cognitive beliefs about, 122
Morrison’s model of, 115–16, 124
the paranoid mind, 144
UHR group treatment targets, 79, 80, 85
depression
Beck Depression Inventory, 33
Calgary Depression Scale, 32–3
FETZ programme, 171, 173, 177
Hamilton Rating Scale, 32, 33
stress and, 54
UHR group treatment targets, 76–7, 79, 80, 81, 82, 84, 85, 86, 87
INDEX

developmental models, ARMS, 80, 81, 135–6, 148

discrepancy, motivational interviewing, 102
drug-induced psychosis, 96
drug interventions see antipsychotic medication
drug use, illicit see substance use

Early Detection & Intervention Team (Birmingham: ED:IT), 81–7
Early Detection & Intervention Team (Salford; EDIT), 111, 115–18, 120
Early Recognition and Intervention Centre for Mental Crises (FETZ), 169–78
early social environments, 133–5

see also childhood trauma
EDIE programme, setting for, 46
EDIE trial, 2–3, 4, 112–13, 131–2
education programmes, 47
see also psychoeducation
emotional dysfunction/distress

cognitive behaviour therapy, 135–7, 146–8
family members’, 154, 155, 156
S-REF model, 116
UHR group treatment targets, 75–81, 82, 84, 85–6, 87–8
emotions, perception of, 171, 174, 177
empathy, 49, 102
engagement, 25, 26, 41, 42–8, 50, 113–14
ED:IT, 81
individuals with BLIPS, 139–42
substance users, 100, 101, 102
enjoyment, FETZ programme, 171, 173–4
environmental stress, 57–8, 134–5, 155
epidemiology of ARMS, 1–2, 4
ethical issues, 3–4, 112
ethnic discrimination, 134
expressed emotion (EE), 57–8, 154–5

family history

assessing at risk people, 29
family interventions and, 159, 162–3
identifying at risk people, 7–8, 14, 43
family members, ARMS and
adapation, 155–6
coping, 155–6
expressed emotion, 154–5
first episode psychosis, 154, 155
future challenges, 182–3
high need families, 159, 160–1
impact of diagnosis, 153–6
informant interviews, 34
support/interventions for, 158–65
case examples, 162–4
consolidating gains, 158, 161, 162
conversion to psychosis, 158, 161–2, 164–5
ED:IT, 83, 84

facilitating recovery, 158, 159–61
FETZ programme, 170
generating explanations, 159–61
impact of, 156–7
managing the crisis, 158–9, 160, 163–4
FETZ (Early Recognition and Intervention Centre for Mental Crises), 169–78
formulation, 25, 35–8, 114–18, 125–6, 137–9
future challenges, 4–5, 181–5

genetic risk

family worry about, 162–3
identifying at risk people, 7–8, 14, 43
“going crazy”, fear of, 45, 113, 123–4
group therapy
ED:IT, 83, 84, 85
families, 160
FETZ programme, 169–78
case example, 176–7
evaluation, 177–8
introduction to, 172–3
positive mood, 171, 173–4, 177
problem solving, 171, 173, 176–7
social skills, 171, 172, 174–6, 177
future challenges, 183

hallucinations

cannabis use and, 97
cognitive therapy for BLIPS, 136–7
meta-cognitive beliefs about, 122, 123–4
Morrison’s models of, 115–16, 117, 124
normalising, 118–19
safety behaviours, 124
trauma and, 79, 80, 118–19
UHR group treatment targets, 79, 80
Hamilton Rating Scale for Anxiety (HRSA), 32, 33
Hamilton Rating Scale for Depression (HRSD), 32, 33
Hassles Scale, 65
help-seekers

common presenting problems, 113
research methodologies, 1–2, 3
help-seeking

engagement and, 42, 46–7, 113, 139–41
stigma as barrier to, 46–7
high risk family history, 7–8, 14
hypomania, 54

identifying the at risk population, 7–21, 43–4
in vivo observations, 34–5
informant interviews, 34
interpersonal threat, 142–3, 144–6, 148
interventions see treatment
interviews, assessment, 28–31, 29

see also semi-structured interview schedules
intrusive thoughts, 120, 121–2
isolated psychotic symptoms, 9, 10, 12

Life Event Interview Schedule, 64–5
life events
stress–psychosis relation, 53–6, 62, 64–5, 118
UHR group treatment targets, 79, 80, 85
locations for therapy, 45–6, 114, 184

media depictions, mental illness, 46, 47
medical interventions see antipsychotic medication
mental health promotion, ED:IT, 87
Mental State Examination, 31
meta-cognitions, 120, 122–4, 135, 146–7, 148
migration, stress and, 58
mindfulness, 183
mood
building positive, 171, 173–4, 177
daily life stress and, 57
identifying at risk people, 9, 10
see also depression
Morrison’s models of psychosis, 115–16, 117, 124
motivational interviewing (MI), 101–3, 104–5

narrative based formulation, 137–8
neuroleptic medication see antipsychotic medication
neurotic symptoms, 9, 10
see also anxiety
normalisation of experiences, 118–19, 141–2, 183

observation of clients, 34–5

PACE clinic
co-morbidity, 77
coping with stress, 63–6
setting, 46
stress management, 67–8
substance use, 98
testing UHR criteria, 15–16
PACE trial, 2–3, 132
paranoia

cognitive interventions, 118, 119, 120, 121–2, 141–8
conceptualisation, 135
Perceived Stress Scale (PSS), 65–6
Personal Assessment and Crisis Evaluation see PACE clinic; PACE trial
personality model of substance use, 95
physical symptoms, 9, 10
pleasurable activities, FETZ programme, 171, 173–4, 177
post-traumatic stress disorder (PTSD), 76, 79, 87

PRIME group
clinic setting, 46
identification of UHR individuals, 20
trial methodology, 2–3
problem solving, FETZ programme, 171, 173, 176–7

prodromes
characterising features of, 8–10
future challenges, 181
most frequent symptoms, 10, 11
predictive accuracy, 129–30
prospective identification, 11–12
social isolation, 43–4
use of term, 1, 130

psychiatric assessment see assessment
psychoeducation
ED:IT, 84
for families, 157, 160, 163, 164–5, 170
FETZ programme, 170, 177
for stress management, 67–8
substance users, 101

psychological treatment, future role, 5, 181, 182–3, 184
see also cognitive behaviour therapy; psychoeducation
psychosis proneness, 12–13
stress and, 62–3

relapse detection studies, 132–3
relapse prodrome, 9
relapse psychotic episodes, 55–6, 57
research issues
epidemiological, 1–2, 4
ethical, 3–4
future developments, 4–5, 181, 182, 184–5
methodological, 2–3
stress–psychosis relation
appraisal of stressors, 58
life event studies, 54–5, 56
psychosis proneness scales, 63
risk factors, UHR research, 78–80
role functioning, engagement and, 43
role play
for client assessment, 35
FETZ programme, 174, 175, 176, 177
rolling with resistance, 103
ruptures in therapeutic alliance, 49–50

S-REF model, emotional dysfunction, 116
safety, environmental, 134–5
safety behaviours, 115, 116, 124–5
Scale of Prodromal Symptoms (SOPS), 20, 43
schizophrenia
expressed emotion, 57–8, 154–5
fear of developing engagement and, 45
family interventions, 162–3
group therapy example, 177
and identification of ARMS group basic symptoms as predictors, 13
family history approaches, 7–8
prodromal features, 8–12
psychosis proneness, 12
stress–psychosis relation coping strategies, 59, 60, 61, 155
expressed emotion, 57–8, 155
life events studies, 53–6
minor stressors, 56–7
quasi-experimental studies, 58
UHR group treatment targets and, 78, 79, 82–3
urbanicity and, 134
Schizophrenia Prediction Instrument, Adult Version (SPI-A), 13, 20
schizophreniform disorder, stress, 54
self-efficacy, 103
self-medication, substance use as, 95
self-monitoring, 34
self-reflectiveness, 135–6
self-regulatory executive function (S-REF) model, 116
self-report scales, 33–4
self-stigma, 46
semi-structured interview schedules, 31–2
CAARMS, 16–20, 32
Life Event Interview Schedule, 64–5
see also Calgary Depression Scale service development, 183–5
settings for therapy, 45–6, 114, 184
sexual abuse, childhood, 78, 79, 134, 135
social anxiety
ED-IT, 84, 85
normalising, 141–2
social environments, early, 133–5
see also childhood trauma
social isolation engagement and, 43–4
UHR group treatment targets, 80, 81, 84, 85
social perception, FETZ programme, 171, 173, 174–5
social skills, FETZ programme, 171, 172, 174–6, 177
state plus trait risk factors, 130–2
stigma engagement and, 46–7, 114
normalisation of experience, 183
service development and, 184
stress, 53–68
environmental, 57–8, 134–5
established psychotic disorders and, 53–61
appraisal of stressors, 58, 155
 coping with, 59–61, 155
expressed emotion, 57–8, 155
life events studies, 53–6
minor stressors, 56–7
quasi-experimental studies, 58
FETZ programme, 170, 177
life events and, 53–6, 62, 64–5, 118
monitoring, 68
UHR group
coping, 61–6, 68, 135
stress management, 67–8
within families, 155–6, 160, 163–4
stress-vulnerability model of psychosis, 27, 35–6, 53, 57–8, 67
BLIPS, 135
family interventions and, 155, 160
FETZ programme, 170
Structured Clinical Interview for DSM-IV (SCID), 32
Structured Interview for Prodromal Symptoms (SIPS), 20
substance use, 93–106
‘at risk’ populations, 97–106
course of psychosis, 95–7
early/first episode psychosis, 94–6, 98, 99–100
established psychosis, 94, 95, 99
rates of, 93–5, 97
treatment principles, 99–106
assessment of clients, 100–1, 104
case example, 104–6
client’s explanatory model, 100–1, 104
motivational interviewing, 101–3, 104–5
psychoeducation, 101
relapse prevention, 104
reviewing substance use, 100
UHR group treatment targets, 76
subthreshold psychotic symptoms see attenuated psychotic symptoms
suicide
assessing at risk people, 30
UHR group treatment targets, 77, 82, 85, 86
survival beliefs, paranoia, 143, 144, 148
suspiciousness, 114, 118, 119
see also paranoia
symptom scales, clinician-rated, 32–3
symptoms of psychosis
ARMS operational criteria, 130–2
basic, 13, 82, 129–30
classificatory systems and, 78
identifying at risk people, 8–16, 43–4
impact on engagement, 44–5, 114
risk factors for developing, 78–80
treating attenuated, 111–26
symptoms of psychosis (Continued)  
see also attenuated psychotic symptoms; brief limited intermittent psychotic symptoms (BLIPS)  

therapeutic alliance, 41, 48–50, 158–9  
see also engagement  

threat  
environmental, 134–5  
interpersonal, 142–3, 144–6, 148  

trait plus state risk factors, 130–2  

trans-theoretical model of behaviour change, 102  

trauma, 134, 135  

UHR group treatment targets, 78, 79, 80, 81, 85, 86  

treatment  
antipsychotic medication, 2–3, 5, 55–6, 83, 104, 112–13, 132, 184  

assessment and, 25–7  
of attenuated psychotic symptoms, 111–26  

for BLIPS, 112–13, 135–48  

ED:IT types, 83–4  

engagement see engagement  

family interventions, 83, 84, 158–64  

formulation, 35, 36–8, 114–18, 125–6, 137–9  

future challenges, 182–5  

group therapy, 83, 84, 85, 160, 169–78  

reluctance to attend, 42–3  

research methodologies, 2–3, 5  

service development, 183–5  

settings for, 45–6, 114, 184  

stigma as barrier to, 46–7  

substance use, 99–106  

targets for UHR group, 75–88  


classificatory systems and, 77–8  

co-morbid disorders, 76–81, 82–3, 84, 85, 86, 87  

ED:IT, 81–7  

emotional dysfunction, 75–81, 82, 84, 85–6, 87–8  

risk factors, 78–80  

therapeutic alliance, 41, 48–50, 158–9  

Ultra High Risk (UHR) for psychosis clients, 1  

assessment, 16–20, 25–35, 100–1, 104  

case formulation, 25, 35–8  

ED:IT, 81–7  

engagement in therapy see engagement  

family support/interventions, 83, 84, 153–65, 170  

future challenges, 182, 184  

group therapy, 83, 84, 85, 169–78  

identification, 12, 13–21  

risk factors for UHR, 78–80  

service development, 184  

stress see stress  

subgroups, 130–2  

see also attenuated psychotic symptoms; brief limited intermittent psychotic symptoms  

substance use, 76, 93, 97–106  

therapeutic alliance, 41, 48–50  

treatment targets, 75–88  

urbanicity, 134–5  

voice hearing see auditory hallucinations  

volitional changes, 9, 10  

vulnerability model  

stress see stress-vulnerability model  

substance use, 95, 98  

warfare, stress–psychosis relation, 58